99 studies found for:    "beta thalassemia"
Show Display Options
Rank Status Study
21 Unknown  Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
Conditions: Thalassemia Major;   Thalassemia Intermedia;   Pulmonary Arterial Hypertension
Intervention: Other: Physician standard-of-care according to ESC/ERS Guidelines
22 Completed Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
23 Recruiting Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
24 Completed Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Condition: Thalassemia Major
Intervention: Drug: Amlodipine
25 Recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product
26 Completed Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
Condition: Thalassemia Major
Intervention:
27 Unknown  Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
Conditions: Beta-Thalassemia;   Bone Marrow Transplantation
Interventions: Drug: Zoledronic acid;   Drug: Placebo
28 Completed Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
Condition: β-Thalassemia Intermedia
Interventions: Drug: hydroxyurea;   Drug: L-carnitine and hydroxyurea;   Drug: hydroxyurea and magnesium chloride;   Drug: hydroxyurea,L-carnitine and magnesium chloride
29 Unknown  Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
Conditions: Beta-thalassemia Major;   Iron Overload
Interventions: Drug: Silymarin (LEGALON);   Drug: Placebo
30 Completed
Has Results
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
Conditions: Transfusional Iron Overload;   β-thalassemia Major;   Pediatric Rare Anemia
Intervention: Drug: Deferasirox
31 Completed Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
32 Completed Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
Condition: Beta-Thalassemia
Interventions: Drug: arginine butyrate;   Drug: epoetin alfa
33 Completed Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major
Condition: Thalassemia Major
Intervention:
34 Completed 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition: Beta Thalassemia
Intervention: Drug: 5-Azacytidine
35 Recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells
36 Withdrawn An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
37 Recruiting ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Condition: Confirmed Diagnosis of ß-thalassemia Major
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
38 Unknown  Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
39 Recruiting Post Hematopoietic Stem Cell Transplantation
Condition: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Intervention: Drug: ICL670
40 Terminated Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
Condition: Thalassemia Major
Interventions: Drug: azacitidine;   Drug: phenylbutyrate

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years